The use of cardiac troponins and B-type natriuretic peptide in COVID-19.
Acta Cardiol
; 77(7): 567-572, 2022 Sep.
Article
in English
| MEDLINE | ID: covidwho-1377937
ABSTRACT
Coronavirus disease 2019 (COVID-19) is still challenging health care systems worldwide. Over time, it has become clear that respiratory disease is not the only important entity as critically ill patients are also more prone to develop complications, such as acute cardiac injury. Despite extensive research, the mainstay of treatment still relies on supportive care and targeted therapy of these complications. The development of a prognostic model which helps clinicians to diverge patients to an appropriate level of care is thus crucial. As a result, several prognostic markers have been studied in the past few months. Among them are the cardiac biomarkers, especially cardiac troponins T/I and brain natriuretic peptide, which seem to have important prognostic values as several reports have confirmed their strong association with adverse clinical outcomes and death. The use of these biomarkers as part of a prognostic tool could potentially result in more precise risk stratification of COVID-19 patients and divergence to an adequate level of care. However, several caveats persist causing international guidelines to still recommend in favour of a more conservative approach to cardiac biomarker testing for prognostic purposes.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Troponin I
/
Troponin T
/
Natriuretic Peptide, Brain
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Acta Cardiol
Year:
2022
Document Type:
Article
Affiliation country:
00015385.2021.1970403
Similar
MEDLINE
...
LILACS
LIS